TherapeuticsMD, Inc. Elects Four Additional Directors

TherapeuticsMD™, Inc. ("Therapeutics" or the "Company") (OCTQB: TXMD), parent company of vitaMedMD™, LLC ("vitaMedMD"), a specialty pharmaceutical company, announced today the election of four additional members to its Board of Directors including Samuel A. Greco, Cooper Collins, Robert V. LaPenta, Jr. and Nicholas Segal. Robert G. Finizio, John C.K. Milligan IV and Dr. Brian Bernick will continue to serve as directors of the Company.

Robert G. Finizio, the Company's Chief Executive Officer, stated, "We are grateful that these gentlemen are joining our board. Their expertise in the areas of healthcare, information technology, branded and generic pharmaceutical products, sales and marketing, new product development, product positioning and equity markets is a huge asset to us as we move forward to expand the reach of our Company and products. We are confident that their involvement will result in positive outcomes for us and will ultimately help us create increased value for our shareholders."

Samuel A. Greco currently serves as Chief Executive Officer and director of CareView Communications, Inc. [OTCQB: CRVW], an information technology provider to the healthcare industry. Greco has spent over thirty years in hospital administration, beginning at an independent city hospital and progressing to Senior Vice President of Financial Operations at Columbia/HCA Healthcare Corporation, the industry's largest healthcare provider. He has become one of the industry leaders in successfully applying these supply chain strategies, vendor partnering and logistics management to improve results and provide significant savings. He was instrumental in the development of the CareView System™ and his extensive contacts and relationships within the industry have been valuable in helping CareView pursue its goals.

Cooper C. Collins is President, Chief Executive Officer and director of Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. Over Mr. Collins' tenure as an executive with Pernix, he has been responsible for increasing the overall growth, profitability and efficiency of the organization, overseeing product development and acquisitions, and managing the capital structure of Pernix.

If you liked this article you might like

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Penn National Gaming, Wynn Resorts: 'Mad Money' Lightning Round

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)